Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06275997 | GAIN Project: Gastric Cancer and Artificial Intelligence(GAIN) | not yet recruiting | N/A | 6,600 | Istituto Clinico HumanitasOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06439550 | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | not yet recruiting | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jun 3, 2024 |
| clinicaltrials |
| NCT06435689 | Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers(I-COMET) | not yet recruiting | — | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06432075 | Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer | not yet recruiting | Early Phase 1 | 20 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | May 29, 2024 | clinicaltrials |
| NCT06426654 | Sintilimab Combined With LDRT for Neoadjuvant Treatment of Locally Advanced dMMR/MSI-H Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 45 | West China HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT06426797 | Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 25 | Peking University People's HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT06423937 | Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 129 | Fudan UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06421220 | Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer | not yet recruiting | N/A | 484 | Qilu Hospital of Shandong UniversityOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06421974 | Effectiveness of Robotic Surgery for Right Colon Cancer | not yet recruiting | N/A | 610 | Sir Run Run Shaw HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06418516 | Early Detection of Esophageal Squamous Cancer With the Capsule Sponge Device(ANGELA) | not yet recruiting | N/A | 340 | Centre of Postgraduate Medical EducationOTHER | 0 | May 17, 2024 | clinicaltrials |
| NCT06276738 | The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease | not yet recruiting | — | 1,000 | Adenocyte, LLCINDUSTRY | 0 | May 14, 2024 | clinicaltrials |
| NCT06385873 | RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer | not yet recruiting | Phase 2 | 32 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 13, 2024 | clinicaltrials |
| NCT06067620 | Robotic Right Hemicolectomy Versus Laparoscopic Right Hemicolectomy(PRORHEM) | not yet recruiting | N/A | 70 | Jeremy MeyerOTHER | 0 | May 10, 2024 | clinicaltrials |
| NCT06409429 | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | not yet recruiting | Phase 2 / Phase 3 | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06409637 | FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation | not yet recruiting | Phase 1 / Phase 2 | 62 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06329947 | A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD | not yet recruiting | Phase 2 | 37 | Rui-hua Xu, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06399172 | OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy(OSPRItaly) | not yet recruiting | — | 50 | OncoSil Medical LimitedINDUSTRY | 0 | May 3, 2024 | clinicaltrials |
| NCT06089369 | Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | not yet recruiting | Phase 3 | 360 | Tongji HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06390982 | Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Apr 30, 2024 | clinicaltrials |
| NCT06391905 | PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS | not yet recruiting | Phase 2 | 60 | Guangdong Provincial People's HospitalOTHER | 0 | Apr 30, 2024 | clinicaltrials |
| NCT06255379 | Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 52 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06388135 | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 4 | 80 | Yang Jianjun, PhDOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06389500 | HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 30 | Harbin Medical UniversityOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06384300 | Financial Incentives and Motivational Intervention to Improve Gastric Cancer Screening in China | not yet recruiting | N/A | 5,000 | Peking UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT06374901 | Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. | not yet recruiting | Phase 2 | 134 | Xiangdong ChengOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06375317 | HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure | not yet recruiting | Phase 2 | 42 | Yehua ShenOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT06375954 | EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) | not yet recruiting | N/A | 96 | Hospital Universitari de BellvitgeOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06373133 | SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer | not yet recruiting | Phase 1 / Phase 2 | 36 | West China HospitalOTHER | 0 | Apr 18, 2024 | clinicaltrials |
| NCT06369896 | Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures(Spy+IDUS) | not yet recruiting | — | 36 | Soonchunhyang University HospitalOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06370754 | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment(FD-IMPACT) | not yet recruiting | Phase 1 / Phase 2 | 117 | Fudan UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06364787 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06361030 | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06349967 | Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer | not yet recruiting | Phase 2 | 59 | West China HospitalOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT06346808 | Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC | not yet recruiting | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06343116 | Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer(NOTABLE-308) | not yet recruiting | Phase 3 | 420 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Apr 2, 2024 | clinicaltrials |
| NCT06339216 | A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Apr 1, 2024 | clinicaltrials |
| NCT06335576 | Establishment of Serum Proteomics Subtypes of Gastric Cancer and Its Clinical Application | not yet recruiting | — | 89 | Shanghai Zhongshan HospitalOTHER | 0 | Mar 28, 2024 | clinicaltrials |
| NCT06331260 | Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 600 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06331273 | Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 800 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06317896 | Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS | not yet recruiting | — | 82 | Zhujiang HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06259058 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06310473 | Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | not yet recruiting | Phase 2 | 30 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06311916 | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. | not yet recruiting | Phase 4 | 312 | Chen XiaopingOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06313554 | Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | N/A | 63 | Fudan UniversityOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06304545 | Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab | not yet recruiting | Phase 2 | 48 | Harbin Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT06301386 | Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients | not yet recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06253598 | Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT06295094 | The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.(EPICURE) | not yet recruiting | Phase 2 | 264 | Odense University HospitalOTHER | 5 | Mar 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2024source: clinicaltrials